ХРОНИЧЕСКАЯ ОБСТРУКТИВНАЯ БОЛЕЗНЬ ЛЕГКИХ КАК ФАКТОР РИСКА РАЗВИТИЯ СЕРДЕЧНО-СОСУДИСТЫХ ЗАБОЛЕВАНИЙ
https://doi.org/10.15829/1728-8800-2016-3-69-73
Аннотация
Тесная взаимосвязь между сердечно-сосудистыми заболеваниями (ССЗ) и хронической обструктивной болезнью легких (ХОБЛ) привлекает к себе внимание в течение последних лет как один из аспектов системных проявлений ХОБЛ. Высокая распространенность ССЗ у больных ХОБЛ объясняется концепцией персистирующего системного низкоинтенсивного воспаления. В настоящем обзоре ХОБЛ рассматривается с позиции фактора риска развития ССЗ, что требует соответствующего мультидисциплинарных диагностического и лечебного подходов.
Об авторах
А. В. Будневский
Воронежский государственный медицинский университет им. Н.Н. Бурденко, Воронеж
Россия
Доктор медицинских наук, профессор, проректор по научно-инновационной деятельности, зав. кафедрой факультетской терапии
Россия
Доктор медицинских наук, профессор, проректор по научно-инновационной деятельности, зав. кафедрой факультетской терапии
Е. Ю. Малыш
Воронежский государственный медицинский университет им. Н.Н. Бурденко, Воронеж
Россия
Кандидат медицинских наук, ассистент кафедры факультетской терапии
Россия
Кандидат медицинских наук, ассистент кафедры факультетской терапии
Список литературы
1. Finkelstein J, Cha E, Scharf SM. Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity. Int J Chron Obstruct Pulmon Dis 2009; 4: 337-49.
2. Sidney SM, Sorel CP, Quesenberry JR, et al. COPD and incident cardiovascular disease hospitalizations and mortality: kaiser permanente medical careprogram. Chest 2005; 128(4): 2068-75.
3. Cui H, Miao D-M, Wei Z-M, et al. Prevalence of cardiovascular disease in subjects hospitalized due to chronic obstructive pulmonary disease in Beijing from 2000 to 2010. J Geriatr Cardiol 2012; 9(1): 5-10.
4. Macchia A, Moncalvo R JJ, Kleinert M, et al. Unrecognized ventricular dysfunction in COPD. Eur Respir J 2012; 39(1): 51-8.
5. Bursi F, Vassallo R, Weston SA, et al. Chronic obstructive pulmonary disease after myocardial infarction in the community. Am Heart J 2010; 160(1): 95-101.
6. Hawkins NM, Huang Z, Pieper KS. Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the valsartan in acute myocardial infarction trial (VALIANT). Eur J Heart Fail 2009; 3: 292-8.
7. Angouras DC, Anagnostopoulos CE, Chamogeorgakis TP, et al. Postoperative and long-term outcome of patients with chronic obstructive pulmonary disease undergoing coronary artery bypass grafting. Ann Thorac Surg 2010; 4: 1112-8.
8. Ford ES, Wheaton AG, Mannino DM, et al. Elevated cardiovascular risk among adults with obstructive and restrictive airway functioning in the United States: a cross-sectional study of the National Health and Nutrition Examination Survey from 2007–2010. Respiratory Research 2012; 13: article 115.
9. Suissa S, Dell’Aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax 2012; 67(11): 957-63.
10. Cao C, Wang R, Wang J, et al. Body mass index and mortality in chronic obstructive pulmonary disease: a meta-analysis. PLoS ONE 2012; 7: 1-8.
11. Man SFP, Connett JE, Anthonisen NR, et al. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax 2006; 10: 849-53.
12. McGarvey LP, John M, Anderson JA, et al. Ascertainment of cause-specific mortality in COPD: operations of the TORCH clinical endpoint committee. Thorax 2007; 62(5): 411-5.
13. Brekke PH, Omland TP, Smith S, et al. Under diagnosis of myocardial infarction in COPD—Cardiac Infarction Injury Score (CIIS) in patients hospitalized for COPD exacerbation. Respir Med 2008; 102(9): 1243-7.
14. Zvezdin B, Milutinov S, Kojicic M, et al. A postmortem analysis of major causes of early death in patients hospitalized with COPD exacerbation. Chest 2009; 136(2): 376-80.
15. Clayton TC, Thompson M, Meade TW. Recent respiratory infection and risk of cardiovascular disease: case-control study through a general practice database. Eur Heart J 2008; 29(1): 96-103.
16. Corrales-Medina F, Madjid M, Musher DM. Role of acute infection in triggering acute coronary syndromes. Lancet Infect Dis 2010; 10(2): 83-92.
17. Huiart L, Ernst P, Ranouil X, et al. Oral corticosteroid use and the risk of acute myocardial infarction in chronic obstructive pulmonary disease. Can Respir J 2006; 13(3): 134-8.
18. Warren-Gash C, Smeeth L, Hayward AC. Inflenza as a trigger for acute myocardial infarction or death from cardiovascular disease: a systematic review. Lancet Infect Dis 2009; 9(10): 601-10.
19. Soteriades ES, Smith DL, Tsismenakis AJ, et al. Cardiovascular disease in US firefighters: a systematic review. Cardiol Rev 2011; 19(4): 202-15.
20. Man SFP, van Eeden S, Sin DD. Vascular risk in chronic obstructive pulmonary disease: role of inflammation and other mediators. Can J Cardiology 2012; 6: 653-61.
21. Theofilogiannakos EK, Anogeianaki A, Tsekoura P, et al. Arrhythmogenesis in patients with stable chronic obstructive pulmonary disease. J Cardiovascr Med 2008; 9(1): 89-93.
22. Malysh EY, Ovsynnikov ES, Semynina NM, et al. State of the autonomic nervous system in patients with chronic obstructive pulmonary disease and hypertension. Vrach-aspirant 2014; 2.1(63): 186-91. Russian (Малыш Е.Ю., Овсянников Е.С., Семынина Н.М. и др. Состояние вегетативной нервной системы у больных хронической обструктивной болезнью легких и артериальной гипертензией. Врач-аспирант 2014; 2.1(63): 186-91).
23. Corbo GM, Inchingolo R, Sgueglia GA, et al. C-reactive protein, lung hyperinflation and heart rate variability in chronic obstructive pulmonary disease—a pilot study. COPD 2013; 10: 200-7.
24. Chhabra L, Sareen P, Perli D, et al. Vertical P-wave axis: the electrocardiographic synonym for pulmonary emphysema and its severity. Indian Heart J 2012; 64(1): 40-2.
25. Warnier MJ, Rutten FH, Numans ME, et al. Electrocardiographic characteristics of patients with chronic obstructive pulmonary disease. COPD 2013; 10(1): 62-71.
26. Warnier MJ, Rutten FH, Anthonius de B, et al. Resting Heart Rate Is a Risk Factor for Mortality in Chronic Obstructive Pulmonary Disease, but Not for Exacerbations or Pneumonia. PLoS One 2014; 9(8): e105152. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4144884/
27. Vanfleteren LE, Franssen FM, Uszko-Lencer NH, et al. Frequency and relevance of ischemic electrocardiographic findings in patients with chronic obstructive pulmonary disease. Am J Cardiol 2011; 108(11):1669-74.
28. Bhatt SP, Nanda S, Kintzer JS. Arrhythmias as trigger for acute exacerbations of chronic obstructive pulmonary disease. Respir Med 2012;106:1134-8.
29. Caglar IM, Dasli T, Caglar TFN, et al. Evaluation of atrial conduction features with tissue doppler imaging in patients with chronic obstructive pulmonary disease. Clinical Research in Cardiology 2012; 101(8): 599-606.
30. McCullough PA, Neyou A. Comprehensive Review of the Relative Clinical Utility of B-Type Natriuretic Peptide and N-Terminal Pro-B-Type Natriuretic Peptide Assays in Cardiovascular Disease. Open Heart Failure J 2009; 2: 6-17.
31. Mueller C, Laule-Kilian K, Frana B, et al. Use of B-type natriuretic peptide in the management of acute dyspnea in patients with pulmonary disease. Am Heart J 2006; 151(2): 471-7.
32. Budnevsky AV, Ovsjannikov ES, Chernov AV. Prognostic value of biomarkers in assessing the effectiveness of treatment of chronic obstructive pulmonary disease (review of the literature). Molodoj uchenyj 2014; 65(6): 284-7. Russian (Будневский А.В., Овсянников Е. С., Чернов А.В. Прогностическое значение биомаркеров в оценке эффективности терапии хронической обструктивной болезни легких (обзор литературы). Молодой ученый 2014; 65(6): 284-7).
33. Tribuntseva LV, Budnevsky AV. System analysis of the effectiveness of treatment of chronic obstructive pulmonary disease in general practice (family medicine). Vestnik novykh meditsinskikh tekhnologiy 2013; 1. http:// www.medtsu.tula.ru/VNMT/Bulletin/E2013-1/4536.pdf Russian (Трибунцева Л.В., Будневский А.В. Системный анализ эффективности терапии хронической обструктивной болезни легких в общей врачебной практике (семейной медицине). Вестник новых медицинских технологий 2013; 1. http:// www.medtsu.tula.ru/VNMT/Bulletin/E2013-1/4536.pdf).
34. Abroug F, Ouanes-Besbes L, Nciri N, et al. Association of left-heart dysfunction with severe exacerbation of chronic obstructive pulmonary disease: diagnostic performance of cardiac biomarkers. Am J Respir Crit Care Med 2006; 174(9): 990-6.
35. Chang CL, Robinson SC, Mills GD, et al. Biochemical markers of cardiac dysfunction predict mortality in acute exacerbations of COPD. Thorax 2011; 66(9): 764-8.
36. Rutten FH, Cramer M-J M, Zuithof N PA, et al. Comparison of B-type natriuretic peptide assays for identifying heart failure in stable elderly patients with a clinical diagnosis of chronic obstructive pulmonary disease. Eur J Heart Fail 2007; 9(6-7): 651-9.
37. Hoiseth AD, Neukam A, Karlsson D, et al. Elevated high-sensitivity cardiac troponin T is associated with increased mortality after acute exacerbation of chronic obstructive pulmonary disease. Thorax 2011; 66: 775-81.
38. Brekke PH, Omland T, Holmdel SH, et al. Determinants of cardiac troponin T elevation in COPD exacerbation — a cross-sectional study. BMC Pulmonary Medicine 2009; 9(1): art.35.
39. Corrales-Medina VF, Serpa J, Rueda AM, et al. Acute bacterial pneumonia is associated with the occurrence of acute coronary syndromes. Medicine (Baltimore) 2009; 88: 154-9.
40. Anthonisen NR, Connett JE, Enright PL, et al. Lung Health Study Research Group. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002; 166: 333-9.
41. Van Eeden SF, Sin DD. Chronic obstructive pulmonary disease: a chronic systemic inflammatory disease. Respiration 2008; 75: 224-38.
42. Malysh EY, Drobysheva ES, Chernov AV. Chronic obstructive pulmonary disease and damage of the cardiovascular system. Molodoj uchenyj 2014; 64(5): 145-8. Russian (Малыш Е.Ю., Дробышева Е. С., Чернов А.В. Хроническая обструктивная болезнь легких и поражение сердечно-сосудистой системы. Молодой ученый 2014; 64(5): 145-8).
43. Miyata R, Hiraiwa K, Cheng JC, et al. Statins reduce ambient particulate matterinduced lung inflammation by promoting the clearance of particulate matter from lung tissues. Chest 2013; 143(2): 452-60.
44. The effect of statins in patients with chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/NCT01151306
Рецензия
Для цитирования:
Будневский А.В., Малыш Е.Ю. ХРОНИЧЕСКАЯ ОБСТРУКТИВНАЯ БОЛЕЗНЬ ЛЕГКИХ КАК ФАКТОР РИСКА РАЗВИТИЯ СЕРДЕЧНО-СОСУДИСТЫХ ЗАБОЛЕВАНИЙ. Кардиоваскулярная терапия и профилактика. 2016;15(3):69-73. https://doi.org/10.15829/1728-8800-2016-3-69-73
For citation:
Budnevsky A.V., Malysh E.Yu. CHRONIC OBSTRUCTIVE LUNG DISEASE AS RISK FACTOR FOR CARDIOVASCULAR DISORDERS. Cardiovascular Therapy and Prevention. 2016;15(3):69-73. (In Russ.) https://doi.org/10.15829/1728-8800-2016-3-69-73
Просмотров:
1236
Послать статью по эл. почте 
